Skip to main
ABVX

Abivax SA (ABVX) Stock Forecast & Price Target

Abivax SA (ABVX) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 58%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Abivax is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. The company is also conducting preclinical studies to evaluate the potential of combination therapy and the use of obefazimod in other inflammatory and immunological diseases. With a best-in-class profile, a strong pipeline, and the potential for a blockbuster drug in the inflammatory bowel disease market, Abivax is well-positioned for success in the biotech industry.

Bears say

Abivax is a clinical-stage biotechnology company focused on developing therapeutics for inflammatory bowel diseases. A bolstered balance sheet and confidence in obe's ability to treat refractory patients may provide some opportunities, however, there are concerns regarding the observed malignancy signals and the lack of correlation between NMSCs and skin lesions, which may limit the commercial potential and overall safety profile of obefazimod. Additionally, discussions with former FDA leaders suggest that obefazimod is unlikely to receive prominent warning language.

Abivax SA (ABVX) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 58% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abivax SA (ABVX) Forecast

Analysts have given Abivax SA (ABVX) a Buy based on their latest research and market trends.

According to 12 analysts, Abivax SA (ABVX) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $152.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $152.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abivax SA (ABVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.